CJC-1295 and Ipamorelin: How Growth Hormone Secretagogue Peptides Work and What the Research Shows

CJC-1295 and ipamorelin are two of the most frequently discussed growth hormone secretagogue (GHS) peptides in research and clinical literature. Both are synthetic compounds designed to stimulate endogenous growth hormone (GH) release, but they act through distinct receptor pathways. This overview, compiled by the Peptide Register as part of its independent research reference library, examines the published evidence on each peptide, their proposed mechanisms, and the important caveats researchers should consider.

Mechanism of Action: Two Pathways to GH Release

CJC-1295 and ipamorelin stimulate growth hormone secretion through different receptor systems, and understanding these mechanisms is central to interpreting the published data.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds to the GHRH receptor on anterior pituitary somatotroph cells, mimicking the action of endogenous GHRH to promote GH synthesis and release. CJC-1295 is a modified GHRH analogue with a drug affinity complex (DAC) that extends its plasma half-life to approximately 6 to 8 days. This extended duration was achieved through the addition of a maleimidopropionic acid linker that binds covalently to serum albumin after injection, as described in early pharmacokinetic studies (Jetté et al., 2005). A non-DAC version, sometimes referred to as modified GRF(1-29), has a considerably shorter half-life measured in minutes rather than days.

Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist, also known as a ghrelin mimetic. Ipamorelin acts on the ghrelin receptor (GHS-R1a) to stimulate GH release through a pathway distinct from GHRH. Unlike earlier ghrelin mimetics such as GHRP-6, ipamorelin has been reported in preclinical studies to stimulate GH release without significantly elevating cortisol or prolactin at comparable doses (Raun et al., 1998). This selectivity is one reason it has attracted research interest, though human data confirming this profile remains limited.

For readers unfamiliar with the terminology used above, the Peptide Register maintains a peptide glossary covering key terms like secretagogue, half-life, and receptor agonist.

Published Clinical and Preclinical Evidence

The clinical evidence base for CJC-1295 and ipamorelin varies significantly in depth and quality.

CJC-1295 with DAC was evaluated in a dose-escalation study in healthy adults published by Teichman et al. (2006). CJC-1295 with DAC increased mean IGF-1 levels by 36% to 69% after multiple doses in a small human study. That study involved 21 subjects across multiple dosing cohorts and reported sustained elevations in GH and IGF-1 over several days following a single injection. However, the sample size was small, the study was short-term, and long-term safety data from controlled trials remain unavailable.

The evidence base for ipamorelin in humans is more limited. Much of the published data comes from animal models. In a porcine model, ipamorelin was shown to promote GH release in a dose-dependent manner (Raun et al., 1998). A small number of human pharmacokinetic studies exist, but large-scale randomized controlled trials (RCTs) evaluating clinical outcomes in humans have not been published as of 2024. Large-scale randomized controlled trials for ipamorelin in humans have not been published as of 2024.

When CJC-1295 and ipamorelin are discussed together, the rationale typically cited is that combining a GHRH pathway agonist with a ghrelin pathway agonist may produce synergistic GH release. Some animal studies support this concept of dual-pathway stimulation. However, peer-reviewed human trial data specifically evaluating the CJC-1295 and ipamorelin combination remains sparse. Most claims about their combined effects are extrapolated from mechanistic reasoning rather than direct clinical evidence.

Researchers can explore structured profiles of these and other peptides in the Peptide Register database.

Evidence Limitations and Research Gaps

Several important limitations should be considered when evaluating the literature on these peptides. Most ipamorelin studies have been conducted in animal models, not humans. The Teichman et al. human study on CJC-1295 with DAC, while informative, involved only 21 subjects and did not evaluate long-term safety or clinical endpoints beyond hormone levels. No published RCTs have evaluated the CJC-1295 and ipamorelin combination in human subjects. Long-term safety profiles for both peptides remain poorly characterized in the peer-reviewed literature. Surrogate markers like IGF-1 elevation do not necessarily translate to meaningful clinical outcomes, and elevated IGF-1 carries its own theoretical risk considerations.

Regulatory Status

CJC-1295 and ipamorelin are not approved by the FDA for any therapeutic indication. In Australia, the TGA has classified certain GHS peptides under Schedule 4 (prescription-only), meaning they can only be legally prescribed by authorized practitioners under specific conditions. Neither peptide has received marketing authorization as a finished pharmaceutical product in any major jurisdiction. Any clinical use occurs outside of approved indications.

The Peptide Register tracks regulatory developments across jurisdictions to provide researchers and clinicians with current scheduling information. This content is strictly educational and does not constitute medical advice or an endorsement of any peptide's use.